ASH 2014 – Castleman's Disease

Long-Term Maintenance with Rituximab in Elderly Patients with Mantle-Cell Lymphoma

ASH 2014 – Castleman's Disease

Antagonism of Immune Effector Function by Ibrutinib or Obinutuzumab versus Rituximab

ASH 2014 – Castleman's Disease

Ibrutinib Alone or in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

ASH 2014 – Castleman's Disease

Data from the SPARK Study: Mutational Analysis of Patients with Primary Resistance to Ibrutinib in Relapsed/Refractory Mantle-Cell Lymphoma

ASH 2014 – Castleman's Disease

International Research Agenda for Multicentric Castleman’s Disease

ASH 2014 – Castleman's Disease

Updates on Treatments for Castleman’s Disease

ASH 2014 – Castleman's Disease

Pathology and Diagnosis of Multicentric Castleman’s Disease

ASH 2014 – Castleman's Disease

The Clinical Features of Multicentric Castleman's Disease

ASH 2014 – Castleman's Disease

Multicentric Castleman’s Disease Overview and Update on Its Pathogenesis

ASH 2014 – Castleman's Disease

Page 2 of 2

1
2